皮膚カンジダ症に対するピマフシン軟膏の治験:18施設における共同研究成績の綜合  [in Japanese] Cutaneous Candidiasis treated with Pimaricin Ointment:Summerized Data collaborated with 18 Dermatological Clinics  [in Japanese]

Access this Article

Author(s)

Abstract

抗カンジダ性抗生物質ピマリシンにつき,4施設で試験管内抗菌価を測定,C. albicansに対してはMICが3.12∼6.25 mcg/mlの範囲に集中した。白癬菌に対しては50∼100 mcg/ml以上であつた。18施設が行なつたピマフシン軟膏(2%にピマリシンを含む)の治験では,カンジダ性間擦疹23例の有効率65.3%,乳児寄生菌性紅斑6例の有効率83.3%口角糜爛5例の有効率80%,外陰膣カンジダ症12例の有効率66.6%,指間糜爛53例の有効率64.2%,爪囲炎71例の有効率52.1%で,全170例の有効率は60.6%であつた。副作用は170例中8例(4.7%で,軽い刺激症状がみられたのみであつた。

The antifungal activity of Pimaricin was studied by 4 dermatological clinics. The results showed that the Pimaricin had the M. I. C. against Candida albicans of 3.12∼6.25 mcg/ml, but against Trichophyton mentagrophytes and Trichophyton rubrum of 50∼100 mcg/ml. Altogether, 170 patients were treated with 2% Pimaricin ointment. Of the 23 patients with intertriginous candidiasis 15 (65.3%) were improved. Of the 6 patients with infantile intertriginous candidiasis (Erythema mycoticum infantile), five (83.3%) were improved. Of the 5 patients with monilial perléche, 4 (80%) were improved. Of the 12 patients with candidal vaginitis, 8 (66.6%) were improved. Of the 53 patients with interdigital candidiasis, 34 (64.2%) were improved. And of the 71 patients with paronychial candidiasis, 37 (52.1%) were improved. Totally of the 170 patients, 103 (60.6%) were improved. Eight (4.7%) of the patients treated observed local irritation or burning, with only one patient noting contact dermatitis due to Pimaricin.

Journal

  • Nishi Nihon Hifuka

    Nishi Nihon Hifuka 31(5), 509-529, 1969

    Western Division of Japanese Dermatological Association

Codes

  • NII Article ID (NAID)
    130004471949
  • NII NACSIS-CAT ID (NCID)
    AN00183881
  • Text Lang
    JPN
  • ISSN
    0386-9784
  • NDL Article ID
    8353516
  • NDL Source Classification
    ZS39(科学技術--医学--皮膚科学・泌尿器科学)
  • NDL Call No.
    Z19-69
  • Data Source
    NDL  J-STAGE 
Page Top